<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136263</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000123</org_study_id>
    <nct_id>NCT03136263</nct_id>
  </id_info>
  <brief_title>Oxytocin and Cognitive Control in Adult ADHD</brief_title>
  <official_title>Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled crossover study of single-dose&#xD;
      intranasal oxytocin (24 IU) in 18-55 year-old men with attention deficit/hyperactivity&#xD;
      disorder (ADHD). Following a screening visit to determine eligibility, participants will&#xD;
      return for two main study visits. During the main study visits, study participants will&#xD;
      receive either oxytocin (Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland) or&#xD;
      placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy), followed by&#xD;
      assessments of cognitive control over attention and behavior. Twenty-four participants will&#xD;
      be randomized 1:1 to one of two drug orders, i.e., oxytocin - placebo or placebo - oxytocin.&#xD;
      In an additional neuroimaging substudy, a subset of participants will undergo task-based and&#xD;
      resting-state functional magnetic resonance imaging (fMRI) following oxytocin/placebo&#xD;
      administration to investigate the effects of oxytocin on fMRI activation and functional&#xD;
      connectivity within the cognitive control network.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Actual">November 5, 2020</completion_date>
  <primary_completion_date type="Actual">November 5, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stop-signal task</measure>
    <time_frame>First and second main study visits (1-4 weeks apart)</time_frame>
    <description>Mean difference in performance on the stop-signal task between the oxytocin and placebo visits (e.g., stop-signal reaction time)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AX-CPT</measure>
    <time_frame>First and second main study visits (1-4 weeks apart)</time_frame>
    <description>Mean difference in performance on the AX-CPT between the oxytocin and placebo visits (AY and BX responses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Category switch task</measure>
    <time_frame>First and second main study visits (1-4 weeks apart)</time_frame>
    <description>Mean difference in performance on the category switch task between the oxytocin and placebo visits (switch costs and target congruency effect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global/local task</measure>
    <time_frame>First and second main study visits (1-4 weeks apart)</time_frame>
    <description>Mean difference in performance on the global/local task between the oxytocin and placebo visits (global precedence effect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simon task</measure>
    <time_frame>First and second main study visits (1-4 weeks apart)</time_frame>
    <description>Mean difference in performance on the Simon task between the oxytocin and placebo visits (Simon effect and Garner effect)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Attention Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Drug order: Oxytocin - placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug order: Placebo - oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)</description>
    <arm_group_label>Drug order: Oxytocin - placebo</arm_group_label>
    <arm_group_label>Drug order: Placebo - oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)</description>
    <arm_group_label>Drug order: Oxytocin - placebo</arm_group_label>
    <arm_group_label>Drug order: Placebo - oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  18-55 years&#xD;
&#xD;
          -  Diagnosis of attention deficit/hyperactivity disorder&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of cardiovascular disease (e.g., hypertrophic cardiomyopathy, valvular heart&#xD;
             disease, coronary heart disease, or coronary artery spasms)&#xD;
&#xD;
          -  History of diabetes mellitus&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  Hematocrit below the normal range&#xD;
&#xD;
          -  Tobacco use&#xD;
&#xD;
          -  Any other significant illness or condition that the investigator determines could&#xD;
             interfere with study participation or safety or put the subject at any unnecessary&#xD;
             risk&#xD;
&#xD;
          -  Excluded at the investigator's clinical judgement of ADHD symptom severity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franziska Plessow, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Franziska Plessow</investigator_full_name>
    <investigator_title>Assistant Investigator/Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Attention</keyword>
  <keyword>Attention deficit/hyperactivity disorder</keyword>
  <keyword>Cognitive control</keyword>
  <keyword>Executive control</keyword>
  <keyword>Executive functions</keyword>
  <keyword>Impulse control</keyword>
  <keyword>Impulsivity</keyword>
  <keyword>Oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

